Regeneron agrees to spend up to $213M to acquire Decibel Therapeutics 

To date, 2023 is shaping up to be a relatively brisk year for M&A deals. A recent case in point is Regeneron’s acquisition of Decibel Therapeutics. The centerpiece of the deal is DB-OTO, a gene therapy intended for patients with otoferlin-related hearing loss. The drug is in its first clinical trial. Regeneron agreed to pay $4.00 per share for Decibel stock with the potential to pay up to $3.50 per share in cash if Decibel hits agreed-upon regulatory milestones for DB-OTO in a specified time frame, bringing the total value of the deal to roughly $213 million.

Last year, Decibel touted DB-OTO’s ability to support otoferlin expression for several weeks before it plateaued. The company said the data for the drug were in line with earlier preclinical research in which mice achieved a functional recovery.

Involved in transmission of sound signals in the inner ear, the protein otoferlin is essential for hearing. Deficiency or mutations in the gene that produces o…

Read more
  • 0

Decibel Therapeutics touts progress with lead gene therapy product candidate DB-OTO

Decibel Therapeutics (NSDQ:DBTX) recently presented preclinical data for DB-OTO at the Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO).

DB-OTO is a dual-vector adeno-associated virus (AAV) investigational gene therapy product candidate for individuals with hearing loss from mutations of the otoferlin gene.

The most recent data showed that otoferlin expression increased for several weeks before plateauing, which was in line with prior research involving mice that achieved stable, functional recovery.

Prior preclinical research found that DB-OTO restored functional otoferlin protein in mice and dose scaling and distribution in non-human primates.

A Phase 1/2 trial is planned for DB-OTO in sensorineural hearing loss.

Also at ARO, the company presented data on proprietary, cell-selective promoters for three of its gene therapy pipeline candidates.

DBTX shares ticked up about 1% to $4.30.

In Septemb…

Read more
  • 0